Okan Aydın

5PUBLICATIONS
33CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 23, 2026
MCV-Neutropenia Risk Score and Overall Survival in HR+/HER2- Advanced Breast Cancer: A Multicenter Retrospective Landmark Analysis.

|Apr 27, 2026
Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study.

|Aug 27, 2025
Bevacizumab Efficacy and Tolerability in Patients with Metastatic Platinum-Sensitive Ovarian Cancer Beyond Progression.

Mert Erciyestepe, Şermin Dinç Sonuşen, Şaban Seçmeler

|Jul 12, 2025
First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.

Mehmet Cem Fidan, Ahmet Emin Öztürk, Okan Aydın

|Nov 12, 2021
Patients with rheumatic diseases are ready to use social media in clinical practice; what about rheumatologists? A cross-sectional survey.

M Erdogan, O Aydin, E Seyahi

Pageof 1

Frequent Collaborators

2 joint publications

Ahmet Emin Öztürk

2 joint publications

Sermin Dinc Sonusen

2 joint publications

Mert Erciyestepe

2 joint publications

Muhammed Mustafa Atcı